IRB review is rarely free, but who pays and how much depends entirely on the study’s context. A faculty investigator running a minimal-risk survey through their own university’s IRB typically never sees an invoice — the cost is folded into the institution’s facilities-and-administrative (F&A, or “indirect cost”) rate, not billed per protocol. An industry sponsor running a multi-site drug trial through a commercial central IRB, by contrast, pays real, itemized fees that can run into the thousands of dollars per study. And an independent or unaffiliated researcher — someone without a university appointment at all — often faces the least predictable and most out-of-pocket path of the three. This guide breaks down each scenario with real fee data where it’s publicly available, and hedges honestly where it isn’t, since commercial IRB pricing is largely negotiated and not uniformly published. For how long each type of review takes rather than what it costs, see How Long Does IRB Approval Take? Typical Review Timelines by Review Type; for background on what a commercial IRB is structurally, see Commercial IRB.
Three cost scenarios, not one number
“How much does IRB approval cost?” doesn’t have a single answer because it depends on which of three fundamentally different arrangements applies:
- Institutional IRB, internally funded research. A researcher at a university, hospital, or research institute submits a study to that institution’s own IRB. In this scenario there is usually no separate per-study fee charged to the investigator — the IRB office’s operating costs are absorbed into the institution’s overhead and recovered through the F&A rate the institution negotiates with federal funders, not billed line-item per protocol.
- Commercial/central IRB, industry-sponsored research. A pharmaceutical, biotech, or medical-device sponsor running a clinical trial pays a commercial (independent) IRB — most commonly Advarra or WCG (WIRB-Copernicus Group) — a real, itemized fee for initial review, continuing review, and amendments. This is genuine fee-for-service pricing, and the sponsor, not the site or the individual investigator, is almost always the one who pays it.
- Independent/unaffiliated researcher access. A researcher with no institutional appointment — a retired academic, an industry professional conducting research outside employment, a community-based practitioner, or a student without a program-affiliated IRB — has no internal IRB to submit to at all, and generally cannot access one for free. They must contract directly with a commercial IRB (or, in some cases, pay an institution’s own “unaffiliated investigator” fee) and pay out of pocket.
The rest of this guide covers each in turn, with real published figures where an IRB or institution makes its fee schedule public.
Institutional IRB review: usually not a line-item cost, with one common exception
For most internally funded academic research — a faculty member’s own federally funded grant, an unfunded student thesis project, or a departmental study — the institution’s own IRB reviews the protocol as part of its standard operating function, the same way a library or a registrar’s office serves the institution without billing each individual user. The IRB office’s staff, board members’ time, and infrastructure are funded through the institution’s general operating budget and its negotiated F&A rate on sponsored awards, not charged back to the investigator per submission.
The common exception is industry-sponsored research reviewed by an institution’s own IRB. When a pharmaceutical or device company funds a study and that institution’s IRB — not a commercial IRB — conducts the review, many universities and academic medical centers do charge the sponsor a real review fee, on the reasoning that industry sponsors, unlike federal grant programs, aren’t already contributing to the institution’s overhead through F&A. Published examples (verified against each institution’s own posted fee page, current as of when checked and subject to change without notice):
- University of California, Irvine: an IRB review fee of $2,940, effective July 2025, for industry-sponsored studies reviewed by UCI’s own IRB.
- University of Wisconsin–Madison: an initial industry-sponsored research review fee of $2,344; a separate $2,000 institutional compliance review fee applies even when the study’s substantive review is conducted by an outside independent/commercial IRB rather than UW’s own board.
- Rutgers University: charges an IRB review fee specifically when the principal investigator is unaffiliated with Rutgers (not Rutgers-paid faculty, staff, students, or fellows) — a direct example of the “unaffiliated investigator” fee pattern discussed further below.
These figures illustrate the general pattern — sponsor-funded review carries a real fee even at nonprofit academic institutions, and an institution’s own compliance-oversight fee can apply on top of a commercial IRB’s separate fee for the same study — rather than a universal rate; every institution sets its own fee schedule, and many publish it on their IRB or sponsored-programs office website. Always confirm the current figure directly with the specific institution’s IRB or research office rather than treating any number here as current pricing.
Commercial/central IRB fees for industry-sponsored trials
Commercial IRBs price review as genuine fee-for-service work, typically billed to the trial sponsor (occasionally to the site, depending on the study budget) as a line item in the overall trial budget, separate from per-patient site payments. Because pricing is largely negotiated and tiered by protocol complexity, few commercial IRBs publish a single universal rate card — but where fee schedules are publicly posted (often by academic medical centers that pass through a named commercial IRB’s rates to their own investigators), real figures are available:
- WCG (WIRB-Copernicus Group): WCG’s published 2026 standard fee schedule (as posted publicly by an academic medical center’s IRB office) lists an initial review fee of $5,900 and a continuing review fee of $3,132 for standard protocol review. WCG also offers tiered service levels (including an expedited, higher-touch “IRB+” option) with correspondingly different pricing, and the standard schedule sits alongside separate fees for amendments, safety-report submissions, and additional sites.
- Advarra: does not publish a single public fee schedule in the way WCG’s standard rate card is posted by third-party institutions; pricing is generally quoted per protocol directly to the sponsor and varies with study complexity, number of sites, and service tier. Budget for a comparable order of magnitude to WCG’s published figures above as a planning starting point, then request Advarra’s actual quote for the specific protocol rather than assuming a fixed number.
Beyond the headline initial-review figure, a full commercial IRB budget line typically has to account for several separate charges, not just one number:
- Initial (full board or expedited) review — the largest single fee, covering first-time protocol review.
- Continuing review — a recurring fee (commonly annual, where continuing review is still required — see Continuing Review (IRB)) for ongoing oversight of an active study.
- Amendments — a separate, typically smaller fee each time the protocol, consent form, or recruitment materials change and require re-review.
- Per-site or per-additional-site fees — multi-site trials commonly carry an incremental charge for each additional participating site beyond the first, since local-context and site-specific documentation still has to be reviewed even when one board serves as the study’s central IRB / single IRB (sIRB).
- Safety reporting and unanticipated-problem submissions — reportable-event reviews outside the standard continuing-review cycle sometimes carry their own fee.
Because these line items stack, the all-in cost of commercial IRB oversight for a multi-year, multi-site industry trial is routinely well into five figures over the study’s life, even though any single fee line (initial review, one continuing review cycle) may look modest in isolation. Sponsors and clinical operations teams typically build the full IRB fee schedule into the trial budget at the protocol-design stage rather than treating it as an incidental line item — see CASRAI’s guide to the broader IRB/REC approval process for what each of these review actions actually requires substantively, separate from what they cost.
What independent and unaffiliated researchers actually pay
A researcher without an institutional appointment — someone conducting research independently, post-retirement, as an industry professional outside their employer’s scope, or as a community-based clinician — cannot submit to a university’s internal IRB the way an employed faculty member can, because institutional IRBs generally review only research conducted under that institution’s own auspices. This leaves genuinely narrower options, and cost is a real, frequently cited barrier:
- Contracting directly with a commercial IRB. The most common route: pay a commercial/independent IRB (Advarra, WCG, or a smaller independent IRB) directly, out of pocket, for review as an individual client rather than through an institution’s negotiated arrangement or a sponsor’s trial budget. Because commercial IRB pricing is generally structured around institutional and industry clients, an individual researcher without that backing can face the same order-of-magnitude fees described above (potentially several thousand dollars for an initial review) for a study with a far smaller budget than a pharmaceutical trial — a mismatch independent-research advocacy resources and smaller commercial IRBs themselves have specifically flagged as a real access barrier, not a minor inconvenience.
- Paying an institution’s “unaffiliated investigator” fee. Some universities, including Rutgers as noted above, will review a study for a principal investigator who is not employed by or enrolled at that institution, for a posted fee specific to unaffiliated investigators — effectively treating the unaffiliated PI the same way it treats an external industry sponsor, as a paying external client rather than an internally funded researcher.
- Smaller or specialty independent IRBs with lower, more accessible pricing. A handful of smaller commercial IRBs market specifically toward independent researchers, small studies, and minimal-risk protocols, sometimes with lower posted rates than the largest commercial IRBs’ standard industry-trial fee schedules — but coverage, accreditation status, and actual pricing vary by provider and should be confirmed directly rather than assumed.
- Affiliating with an institution that has IRB infrastructure. For some independent researchers, the more practical and lower-cost path is a formal affiliation, visiting-scholar appointment, or collaboration with a university or research institute that already has IRB access, rather than paying full commercial rates as an unaffiliated individual. This isn’t always available, but it’s worth exploring before defaulting to direct commercial-IRB contracting.
There is no single, universal “independent researcher rate” published across the industry — pricing for this exact situation is one of the least standardized and least transparently published corners of IRB fee structures, and multiple independent-research resources note this explicitly rather than pointing to a fixed number. The realistic planning approach is to request a direct quote from at least one or two commercial IRBs for the specific protocol (risk level, procedures, population, single vs. multi-site) before assuming a figure, and to budget for the initial-review fee as the largest single line item, with continuing review and any amendments as recurring costs on top of it if the study runs longer than a year.
Who actually pays, by scenario
| Scenario | Who typically pays | Fee structure |
|---|---|---|
| Internally funded research at institution’s own IRB | Institution (via F&A/overhead recovery) | No separate per-study invoice to the investigator in most cases |
| Industry-sponsored trial, institution’s own IRB reviews it | Industry sponsor | Institution-set review fee, commonly $2,000-$3,000+ per published examples above; varies by institution |
| Industry-sponsored trial, commercial/central IRB reviews it | Industry sponsor (built into the trial budget) | Itemized: initial review, continuing review, amendments, per-site fees — WCG’s 2026 published schedule: $5,900 initial / $3,132 continuing, as one concrete reference point |
| Independent/unaffiliated researcher, no institutional IRB | The researcher directly, out of pocket (occasionally a grant or sponsor, if one exists) | Commercial-IRB rates or an institution’s posted unaffiliated-investigator fee; least standardized, least publicly transparent of the four scenarios |
Treat every dollar figure in this guide as illustrative of real, currently-published pricing at specific institutions and IRBs at the time it was checked — not as a fixed, universal rate. IRB fee schedules change, vary by protocol complexity and review category (exempt, expedited, or full board — see Expedited Review vs. Full Board Review for how review category itself affects both timeline and, indirectly, cost), and are frequently negotiated case by case for industry sponsors. Always request the current, protocol-specific fee schedule directly from the IRB or institution involved before building a budget around any number in this guide.
Frequently asked questions
Do university IRBs charge researchers for review?
Generally not for internally funded research by the institution’s own employed or enrolled researchers — that cost is absorbed into the institution’s overhead. Many universities do charge a review fee, however, when the research is industry-sponsored or when the principal investigator is unaffiliated with the institution; see the published examples above.
How much does a commercial IRB charge for initial review?
There is no single industry-wide rate. As one concrete, currently published reference point, WCG’s 2026 standard fee schedule lists a $5,900 initial review fee and a $3,132 continuing review fee; other commercial IRBs price similarly but not identically, and fees scale with protocol complexity, number of sites, and service tier. Always request a specific quote rather than assuming a fixed figure.
Who pays for IRB review on an industry-sponsored clinical trial — the sponsor or the site?
The sponsor almost always pays IRB review fees, whether the review is conducted by a commercial/central IRB or by a participating site’s own institutional IRB reviewing the sponsor’s protocol. IRB fees are typically built into the overall trial budget the sponsor negotiates with each site, separate from per-patient enrollment payments.
Can an independent researcher without a university affiliation get IRB approval?
Yes, but generally not for free and not through a university’s internal IRB, which typically reviews only research conducted under that institution’s own auspices. The realistic paths are contracting directly with a commercial IRB and paying out of pocket, paying an institution’s specific unaffiliated-investigator fee where one exists, or arranging a formal institutional affiliation that provides IRB access. Cost and access for this specific situation are widely cited as a real, under-addressed barrier for independent researchers.
Does a faster or expedited IRB review cost more?
Review category (exempt, expedited, or full board) is determined by a study’s actual risk profile and procedures, not chosen to save money or time, so a study can’t be shifted to a cheaper or faster category just by request. Some commercial IRBs do offer a premium, higher-touch service tier at additional cost for sponsors who want faster turnaround within whatever category the protocol actually qualifies for.
Related CASRAI resources
- How Long Does IRB Approval Take? Typical Review Timelines by Review Type — the timeline-focused companion to this cost-focused guide.
- Commercial IRB — what distinguishes a commercial/independent IRB from an institutional one.
- Advarra IRB — one of the two largest commercial IRBs, and its role as a central IRB for multi-site trials.
- Central IRB / Single IRB (sIRB) — how central-IRB reliance review works, including per-site fee implications.
- Continuing Review (IRB) — the recurring review process that carries its own separate fee.
- IRB/REC Approval Process: What Needs Review and What Doesn’t — what each review action substantively requires.
- The IRB Application: What to Include, How to Prepare It, and Why It Gets Sent Back — reducing delay and re-review costs from an incomplete first submission.
- IRB (Institutional Review Board) — foundational definition.
